GlobeNewswire by notified

Nicklaus Children’s Health System, Philips to provide innovative patient and staff experience, helping to enhance outcomes for the smallest of patients

Share

April 30, 2024

Philips AI-enabled diagnostic and experiential technologies help put patients at ease while empowering staff with faster, high-quality scans and increased diagnostic confidence

Amsterdam, the Netherlands, and Miami, US –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Nicklaus Children’s Health System, a nationally recognized leader in pediatric care, today announced a 10-year long-term strategic collaboration aimed at enhancing the patient and staff experience, enhancing outcomes and driving innovation in pediatric care. Serving over 500,000 patients a year, Nicklaus Children’s will adopt Philips technologies such as the Ingenia Ambition X MR and EPIQ CVx ultrasound, with AI-enabled radiology workflow solutions to reduce exam times and the need for rescans, while increasing diagnostic confidence, resulting in faster diagnosis and treatment for patients. The addition of patient experience technologies such as Philips Ambient Experience, Kitten Scanner and Scan Buddy App, will help put patients at ease during MRIs by showing them what to expect [1] and empowering them during the scan to help reduce the need for sedation [2] and further shortening exam times. 

Nicklaus Children’s will be the first mobile adoption of the virtually helium-free [3] Philips Ambition X MR, which never needs Helium refilling, and can be discharged or re-energized quickly utilizing the EasySwitch solution, which allows for a controlled ramp down of the magnet, minimizing patient disruptions. With the addition of advanced SmartWorkflow and SmartSpeed MR technologies, staff can automate exam set-up and speed up exam time by up to 65% [4]. Experiential technologies such as the Philips Scan Buddy app, let patients learn about the MR procedure at home with playful characters, educational videos and games. Within the exam area, kids can play with the Kitten Scanner, a miniature MR that allows them to discover how it works. Finally, within the exam room itself, the Philips Ambient Experience with dynamic lighting, video projection, and sound further empowers children and helps put them at ease. Giving kids a sense of control over the situation improves the chance of a successful procedure and helps reduce the need for sedation. 

“Philips shares our commitment to innovation, and patient safety and quality, and has taken the time to understand our care goals and the unique Nicklaus Children's experience we work to deliver,” said Matthew A. Love, president, and CEO of Nicklaus Children’s Health System. “This means understanding that you cannot just make a smaller version of an adult radiology solution for our patients, and that sick kids don’t necessarily stay still for studies. More importantly, if we can make things fun and give each child confidence about the procedure, we can alleviate some of the stress they and their families may be feeling as part of the treatment process.”

Nicklaus Children’s will enhance its cardiac care with the Philips EPIQ CVx and Compact 5500CV AI-enabled ultrasound systems which automate measurements and strain quantification to reduce quantification time by 51% [5] and help sonographers reduce exam time for 2D imaging by 20% [6] while reducing inter-operator variability. TrueVue imaging technology will help interpretation of structural heart disease progression and communication between echocardiographers and interventionalists, providing crucial clinical information, further increasing diagnostic confidence for improved procedure guidance and patient outcomes. 

“Nicklaus Children’s understands that it isn’t just about the technology, it is about creating a healthy future for every child, giving their families and their staff the most precious commodity there is – time,” said Jeff DiLullo, Chief Region Leader for Philips North America. “This is why we develop these systems end-to-end with the smallest of patients in mind, working with child psychologists, not just engineers, to understand how we can improve their experience. Nicklaus Children’s is one of the best pediatric health systems with the highest survival rates in the nation, and if we can help their clinicians with pediatric coaching solutions and AI-enabled solutions to quickly find the answers they need to deliver exceptional outcomes, we can also give families hope.”

[1] Scan Buddy: A Gamified App to Prepare Children for an MRI Scan | SpringerLink
[2] Kitten Scanner reduces the use of sedation in pediatric MRI (sagepub.com)
[3] BlueSeal contains only a fraction of the liquid helium (< 0.5% or 7 liter)* *Compared to the Ingenia 1.5T ZBO magnet
[4] Compared to examinations without SmartSpeed imaging
[5] VM9 claims document 270472
[6] VMQ9.0 Claims Evidence Report

For further information, please contact:

Mark Groves
Philips External Relations
Tel.: +31 631 639 916
E-mail: mark.groves@philips.com

Silvie Casanova
Philips North America
Tel: +1 781 879 0692
Email: silvie.casanova@philips.com

Nathalie Medina
Nicklaus Children’s Health System
Tel: 305 663-8556
Nathalie.Medina@Nicklaushealth.org

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,100 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Nicklaus Children’s Health System: Where Children Matter Most

Nicklaus Children’s Health System (NCHS) is the parent organization of Nicklaus Children’s Hospital, South Florida’s only licensed specialty hospital exclusively for children. The 307-bed nonprofit hospital was founded in 1950 by Variety Clubs International and is renowned for excellence in all aspects of pediatric medicine, with many programs routinely ranked among the nation’s best by U.S. News & WorldReport. The health system also includes Nicklaus Children’s Hospital Foundation, the organization's 501c3 fundraising arm; a network of nonprofit outpatient and urgent care centers situated in Miami-Dade, Broward, Palm Beach and Martin counties; a nonprofit physician practice subsidiary; and an ambulatory surgery center. NCHS is the region’s only healthcare system exclusively for children.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

IDEX Biometrics – Number of shares in Tranche 1 vs Tranche 2 in the private placement on 15 May 202420.5.2024 23:52:54 CEST | Press release

Reference is made to the stock exchange announcement by IDEX Biometrics ASA (the “Company”) on 15 May 2024 regarding a successful private placement of shares. By inadvertence, the announcement contained a slight error in the allocation of private placement shares between Tranche 1, as issued by the Board pursuant to an authorization to issue shares granted by the extraordinary general meeting dated 21 December 2023, and Tranche 2, to be issued subject to approval by an extraordinary general meeting to be called and scheduled for on or about 12 June 2024. The correct number of Tranche 1 shares is 27,940,213, and the correct number of Tranche 2 shares is 5,393,120, each having a par value of NOK 0.15, with a subscription price of NOK 1.65 per share in the private placement. Consequently, following the issuance of Tranche 1 shares, the Company's share capital is increased with NOK 4,191,031.95 from NOK 42,018,983.25 to NOK 46,210,015.20, and the Company will have 308,066,768 shares issued

INVNT™ ANNOUNCED AS SPONSOR AND CO-PRODUCER OF DISCOVERY STAGE AT SXSW SYDNEY® 202420.5.2024 23:00:00 CEST | Press release

Also named as an endorsed Creative Experiential Partner for the 2024 event Sydney, May 20, 2024 (GLOBE NEWSWIRE) -- INVNT™, the Experiential Disrupter Agency, has today been announced as the sponsor and co-producer of the SXSW Sydney 2024 Discovery Stage after a successful collaboration at last year’s inaugural event. For the second consecutive year, INVNT will bring its world-class expertise in production and innovative brand storytelling and “Challenge Everything” ethos to SXSW Sydney, where it will continue its legacy of hosting, curating and presenting the Discovery Stage and activating across the event’s key pillars of Tech & Innovation, Music, Games and Screen. Featured within the SXSW Sydney Tech & Innovation Expo, the 2024 Discovery Stage will play host to inspiring innovation leaders who are redefining industry norms and will be a place to explore the latest developments in technology and meet startup founders who are poised to disrupt the status quo. As last year’s Discovery

Nokia Corporation: Repurchase of own shares on 20.05.202420.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 20 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 20.05.2024 Espoo, Finland – On 20 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL370,3933.56CEUX--BATE--AQEU--TQEX--Total370,3933.56 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM20.5.2024 20:15:00 CEST | Press release

Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in more than a decadeand first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024. Late-breaking data were presented from the NOTUS phase 3 study evaluating the investigational use of Dupixent® (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy (nearly all on triple therapy) and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). The NOTUS study confirmed the positive results demonstrated in the landmark phase 3 BOREAS s

Medarbejdervalgt bestyrelsesmedlem Berit Kjerulf er død20.5.2024 18:12:43 CEST | pressemeddelelse

Selskabsmeddelelse for ROCKWOOL A/S Meddelelse nr. 25 – 2024 til Nasdaq Copenhagen 20. maj 2024 Medarbejdervalgt bestyrelsesmedlem Berit Kjerulf er død Det er med stor sorg, at vi meddeler, at ROCKWOOL medarbejder og bestyrelsesmedlem Berit Kjerulf og hendes mand er omkommet i en brand i deres hjem i Jylland i weekenden. Medarbejderne i ROCKWOOL valgte Berit Kjerulf til at repræsentere dem i bestyrelsen i 2022. Berit har været ansat i ROCKWOOL siden 2005. Hun og hendes mand efterlader sig to voksne børn. Bestyrelsesformand Thomas Kähler udtaler, "Berit var et værdsat medlem af ROCKWOOL familien, en højt værdsat medarbejder og et hårdtarbejdende medlem af bestyrelsen. Det er svært at beskrive den følelse af sorg, hendes bortgang skaber. På vegne af bestyrelsen og alle vores kolleger udtrykker jeg vores dybeste medfølelse til Berit’s børn og hendes kære. Vi vil naturligvis gøre alt, hvad vi kan for at støtte Berit’s familie og vores kolleger i den kommende tid”. Vi vil informere om Berit

HiddenA line styled icon from Orion Icon Library.Eye